Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobemstomig vs Pembrolizumab in Advanced NSCLC
NCT05775289Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2023
- Primary completion
- Jun 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of tobemstomig in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Mar 2023; status: completed.
02
Drugs
tobemstomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05775289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775289.